Fulgent Genetics (FLGT) Cash & Current Investments (2015 - 2026)

Fulgent Genetics has disclosed Cash & Current Investments across 12 years of filings, most recently posting $276.3 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $276.3 million, down 13.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $276.3 million (down 13.74% YoY), and the FY2025 annual result was $336.1 million, up 30.21% from the prior year.
• Cash & Current Investments came in at $276.3 million for Q1 2026 at Fulgent Genetics, down from $336.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $585.1 million in Q1 2022 to a low of $213.1 million in Q3 2024.
• The 5-year median for Cash & Current Investments is $375.8 million (2025), against an average of $385.3 million.
• Across the five-year window, Cash & Current Investments jumped 87.02% in 2022 and plunged 54.45% in 2024, its largest moves.
• Fulgent Genetics' Cash & Current Investments stood at $526.2 million in 2022, then decreased by 19.4% to $424.2 million in 2023, then tumbled by 39.15% to $258.1 million in 2024, then surged by 30.21% to $336.1 million in 2025, then slipped by 17.79% to $276.3 million in 2026.
• The last three Cash & Current Investments figures came in at $276.3 million (Q1 2026), $336.1 million (Q4 2025), and $375.8 million (Q3 2025), per Business Quant data.